Amicus Therapeutics Inc (FOLD)

13.53
NASDAQ : Health Care
Prev Close 13.61
Day Low/High 13.21 / 13.80
52 Wk Low/High 4.41 / 14.05
Avg Volume 3.59M
Exchange NASDAQ
Shares Outstanding 164.04M
Market Cap 2.23B
EPS -1.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

This $3 Biotech Stock Is Making an 11% Move Thursday

This $3 Biotech Stock Is Making an 11% Move Thursday

In focus.

Trump's FDA: A Friendlier Biotech Sheriff

Trump's FDA: A Friendlier Biotech Sheriff

There still will be winners and losers, but the new administration's FDA is a net plus for the industry.

Arena Pharma's Stock Could Still Double Even After Tuesday's Epic Run

Arena Pharma's Stock Could Still Double Even After Tuesday's Epic Run

Big gains could be ahead for investors willing to stick with the stock, according to one firm.

Amicus Therapeutics Submits Japanese New Drug Application For Migalastat For Fabry Disease

Represents World's Second Largest Diagnosed Global Fabry Patient Population

Biotech Movers: Akari, Array, Amicus

Biotech Movers: Akari, Array, Amicus

Akari Therapeutics, Array BioPharma and Amicus Therapeutics were among the biotech movers in premarket trading on Wednesday.

Keep Biotech Trigger Fingers Holstered

Keep Biotech Trigger Fingers Holstered

Three names show how fast biotechs can become oversold when the market acts in knee-jerk fashion.

Biotech Movers: Ionis, Alnylam, Amicus, Minerva

Biotech Movers: Ionis, Alnylam, Amicus, Minerva

Ionis Pharmaceuticals, Alnylam Pharmaceuticals, Amicus Therapeutics and Minerva Neurosciences were among the biotech movers in premarket trading on Monday.

Amicus Therapeutics (FOLD) Shares Cross Below 200 DMA

In trading on Monday, shares of Amicus Therapeutics Inc crossed below their 200 day moving average of $6.78, changing hands as low as $6.73 per share. Amicus Therapeutics Inc shares are currently trading down about 1.7% on the day.

Vegas Baby: Rolling '777s' in Biotech

Vegas Baby: Rolling '777s' in Biotech

Three small-cap biotechs with attractive risk/reward profiles.

Interesting FOLD Put And Call Options For May 19th

Investors in Amicus Therapeutics Inc saw new options become available this week, for the May 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the FOLD options chain for the new May 19th contracts and identified one put and one call contract of particular interest.

Amicus Therapeutics Launches Galafold™ (Migalastat) For Treatment Of Fabry Disease In Italy

Ministry of Health Publishes Final Guidance Covering Reimbursement of Galafold for Fabry Disease

Amicus CEO John Crowley, Not His Daughter Megan, Might Compel Trump to Make Big Changes at FDA

Amicus CEO John Crowley, Not His Daughter Megan, Might Compel Trump to Make Big Changes at FDA

Absent specific policy details, Trump's speech leaves investors guessing about his real plans for the FDA and the drug approval process. He has not yet named an FDA commissioner.